EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Caveolin-1-Related Intervention for Fibrotic Lung Diseases

Sreerama Shetty, Steven Idell iD

Cells · 09.02.2023 · 12 (4) · 554

DOI: 10.3390/cells12040554 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 09.02.2023. Verfasst von Sreerama Shetty und 1 weiteren Autor:innen. Beteiligte Einrichtung: Texas Lung Injury Institute, Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, 11937 US Highway 2…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD) for which there are no effective treatments. Lung transplantation is the only viable option for patients with end-stage PF but is only available to a minority of patients. Lung lesions in ILDs, including IPF, are characterized by alveolar epithelial cell (AEC) senescence and apoptosis and accumulation of activated myofibroblasts and/or fibrotic lung (fL) fibroblasts (fLfs). These composite populations of fLfs show a high rate of basal proliferation, resist apoptosis and senescence, and have increased migration and invasiveness. They also more readily deposit ECM proteins. These features eventuate in progressive destruction of alveolar architecture and loss of lung function in patients with PF. The identification of new, safer, and more effective therapy is therefore mandatory for patients with IPF or related ILDs. We found that increased caveolin-1 and tumor suppressor protein, p53 expression, and apoptosis in AECs occur prior to and then with the proliferation of fLfs in fibrotic lungs. AECs with elevated p53 typically undergo apoptosis. fLfs alternatively demonstrate strikingly low basal levels of caveolin-1 and p53, while mouse double minute 2 homolog (mdm2) levels and mdm2-mediated degradation of p53 protein are markedly increased. The disparities in the expression of p53 in injured AECs and fLfs appear to be due to increased basal expression of caveolin-1 in apoptotic AECs with a relative paucity of caveolin-1 and increased mdm2 in fLfs. Therefore, targeting caveolin-1 using a caveolin 1 scaffolding domain peptide, CSP7, represents a new and promising approach for patients with IPF, perhaps other forms of progressive ILD or even other forms of organ injury characterized by fibrotic repair. The mechanisms of action differ in the injured AECs and in fLfs, in which differential signaling enables the preservation of AEC viability with concurrent limitation of fLf expansion and collagen secretion. The findings in three models of PF indicate that lung scarring can be nearly abrogated by airway delivery of the peptide. Phase 1 clinical trial testing of this approach in healthy volunteers has been successfully completed; Phase 1b in IPF patients is soon to be initiated and, if successful, will be followed by phase 2 testing in short order. Apart from the treatment of IPF, this intervention may be applicable to other forms of tissue injury characterized by fibrotic repair.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Idiopathic Pulmonary FibrosisMiceAnimalsCaveolin 1LungPeptides

Stichwörter der Autor:innen

AECsCSP7Caveolin-1IPFdry powder inhalational therapyfLfsinterstitial lung diseasesp53pulmonary fibrosis

Substanzen

Tumor Suppressor Protein p53Caveolin 1Peptides

Autor:innen und Institutionen

  • Texas Lung Injury Institute, Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, 11937 US Highway 271, Tyler, TX 75708, USA.

ORCID-Profile: Steven Idell

Förderung

  • NHLBI NIH HHS
  • NIEHS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Shetty, S., & Idell, S. (2023). Caveolin-1-Related Intervention for Fibrotic Lung Diseases. Cells, 12(4), 554. https://doi.org/10.3390/cells12040554

Vancouver

Shetty S, Idell S. Caveolin-1-Related Intervention for Fibrotic Lung Diseases. Cells. 2023;12(4):554. doi:10.3390/cells12040554

BibTeX
@article{Shetty2023,
  author = {Shetty, Sreerama and Idell, Steven},
  title = {Caveolin-1-Related Intervention for Fibrotic Lung Diseases},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {554},
  doi = {10.3390/cells12040554}
}
Kostenlos starten →